From September, Dr Baselga combines the scientific management of the Vall d’Hebron Institute of Oncology (VHIO) with his new appointment at the Hematology & Medical Oncology Division at the Cancer Center of the Massachusetts General Hospital at Harvard Medical School in Boston.
Related Posts
VHIO collaborates in study identifying a novel therapeutic target for triple-negative breast cancer
• The PIM1 proto-oncogene evidenced as new therapeutic target through which to sensitize triple-negative breast tumours to chemotherapy• PIM1…
05 Nov 2016
VHIO awarded International Certification for Project Management in Cancer Biomedical Research
Fulfilling the requirements of the standard ISO 9001:2008, VHIO is one of the few research institutes in Europe to have…
06 Jun 2013
Josep Tabernero: 1 of the 11 Catalonia-based candidates for DIARIO MEDICO´s Top 25 ambassadors of biomedicine and healthcare in Spain – VOTING NOW OPEN
In celebration of its 25th Anniversary, DIARIO MEDICO – one of Spain´s leading medical periodicals, has just opened a poll…
04 Jul 2017
Nature Reviews Cancer Perspectives/Opinion article: an exploration of the precise and predictive powers of PDX models – now and in the future
In a recent Perspectives/Opinion article* published online in Nature Reviews Cancer, members of the EurOPDX Consortium, including VHIO´s Joaquín Arribas,…
16 Feb 2017
Studies Report New Findings on Treatment Options for Mesothelioma
High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery; PD-L1 protein a possible immunotherapy target Is PD-L1 a…
30 Sep 2014
VHIO tests a new combination of drugs for HER2-positive breast cancer without the adverse effects of conventional chemotherapy
This research studied the action mechanisms of two drugs—lapatinib and trastuzumab—in combination for the treatment of HER2-positive breast cancer. Lapatinib is a molecule which, when combined with trastuzumab, neutralizes the activity of the HER2 receptor and improves the effect of the antibody
07 Sep 2010
NEJM:Two-drug combination, nab-paclitaxel and gemcitabine, improves survival in pancreatic cancer
• Investigators at the Vall d´Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO), have participated in an…
17 Oct 2013
VHIO Spin-Off Mosaic Biomedicals co-recipient of CataloniaBio´s Biosuccess Award of the Year
Wednesday night´s annual Night of CataloniaBio gala event convening some 250 entrepreneurs, executives, investors, and leading scientists from within the…
17 Mar 2017
ecancer TV´s interview with Joan Seoane: driving discovery to more precisely characterize, track and treat glioblastoma
During the recently celebrated 24th Biennial Congress of the European Association for Cancer Research (EACR), 09 – 12 July, Manchester…
25 Jul 2016
VHIO´s Joan Seoane: Scientific Chair of EACR´s forthcoming conference: Defence is the Best Attack – Immuno-Oncology Breakthroughs, 09 – 11 October 2017, Barcelona, Spain
Tremendous progress marked to-date in more effectively training and harnessing the immune system to recognize, hone in on, and destruct…
24 Apr 2017
VHIO study exploits premature aging of cells as a treatment strategy for HER2+ breast tumors
Barcelona, May 22, 2015.– Research led by the Vall d’Hebron Institute of Oncology´s Growth Factors Group headed by Joaquín Arribas,…
25 May 2015
Backing breast cancer research of excellence: the Conquer Cancer Foundation awards VHIO´s Cristina Cruz
Celebrated last week during the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), Cristina Cruz receives a…
04 Jun 2015
Study describes phenomenon of resistance to novel therapy for advanced lung cancer
• Resistance to targeted therapies for lung cancer, the most common cancer worldwide, represents one of the major limitations in…
05 May 2015
New proposal for combined therapy proves effective against a notoriously resistant HER2+ breast cancer subtype
➢ The combination of chemotherapy and selective therapy with trastuzumab has for the very first time been shown as an…
13 Oct 2014
